alexa

GET THE APP

José Antonio Mata-Marín | OMICS International
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 1337

Journal of Gastrointestinal & Digestive System received 1337 citations as per google scholar report

Journal of Gastrointestinal & Digestive System peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

José Antonio Mata-Marín

Departamento de Infectología adultos. Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México

Biography

Dr. Jose works at Departamento de Infectología adultos. Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México.
Have research interest in Genotype 1; Boceprevir; Sustained virological response; Anemia; Experienced patients.
Have taken Gastrointestinal & Digestive System as the subject of study. 
Publications

Boceprevir in Mexico: Experience in a Series of Cases

There are many new drugs for HCV treatment. First generation protease inhibitors are about to be discontinued. However in developing countries the likelihood of access to these new drugs is vague. As in other poor countries, in Mexico we only have peg interferon and ribavirin for HCV treatment and the costs of the new therapies are hard to fill. Th... Read More»

José Antonio Mata-Marín, Jorge Luis Sandoval-Ramirez, Bulmaro Manjarrez-Tellez, Jesus Enrique Gaytán-Martínez and Alberto Chaparro-Sánchez

Research Article: J Gastrointest Dig Syst 5: 317

DOI: 10.4172/2161-069X.1000317

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Top